DeLord et al
1 recently reported an interesting case of vaginal stenosis following allogeneic BMT. We have recently seen two women with severe dysparunia in spite of being on adequate estrogen replacement therapy as soon as they were discharged from the BMT unit.
Both had received TBI, one 10 Gy in one fraction with the lungs shielded to receive only 9 Gy, and one 2.5 Gy twice daily for 2 days at a high dose rate. Both had CML in first chronic phase and both developed extensive cutaneous chronic GVHD after allografts from HLA-identical siblings. They were treated with cyclosporin and prednisolone at conventional doses and both had a Karnofsky score of 80-90% despite their chronic GVHD. Both lived in stable marriages but could not tolerate vaginal penetration because of pain and bloody discharge. As their symptoms were thought to be manifestations of chronic GVHD they were treated locally with a mild hydrocortisone preparation (Ficortril, Pfizer 1% twice to three times daily) and both recovered completely in about 2 weeks. It is probably important that the hydrocortisone ointment should be used early in the course of chronic graft-versus-host disease before more severe disease as described by DeLord et al makes treatment impossible. 
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